Literature DB >> 12660252

Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes.

Takahisa Furuta1, Haruyuki Takemura, Zhi-Yong Liao, Gregory J Aune, Christophe Redon, Olga A Sedelnikova, Duane R Pilch, Emmy P Rogakou, Arkady Celeste, Hua Tang Chen, Andre Nussenzweig, Mirit I Aladjem, William M Bonner, Yves Pommier.   

Abstract

DNA double-strand breaks originating from diverse causes in eukaryotic cells are accompanied by the formation of phosphorylated H2AX (gammaH2AX) foci. Here we show that gammaH2AX formation is also a cellular response to topoisomerase I cleavage complexes known to induce DNA double-strand breaks during replication. In HCT116 human carcinoma cells exposed to the topoisomerase I inhibitor camptothecin, the resulting gammaH2AX formation can be prevented with the phosphatidylinositol 3-OH kinase-related kinase inhibitor wortmannin; however, in contrast to ionizing radiation, only camptothecin-induced gammaH2AX formation can be prevented with the DNA replication inhibitor aphidicolin and enhanced with the checkpoint abrogator 7-hydroxystaurosporine. This gammaH2AX formation is suppressed in ATR (ataxia telangiectasia and Rad3-related) deficient cells and markedly decreased in DNA-dependent protein kinase-deficient cells but is not abrogated in ataxia telangiectasia cells, indicating that ATR and DNA-dependent protein kinase are the kinases primarily involved in gammaH2AX formation at the sites of replication-mediated DNA double-strand breaks. Mre11- and Nbs1-deficient cells are still able to form gammaH2AX. However, H2AX-/- mouse embryonic fibroblasts exposed to camptothecin fail to form Mre11, Rad50, and Nbs1 foci and are hypersensitive to camptothecin. These results demonstrate a conserved gammaH2AX response for double-strand breaks induced by replication fork collision. gammaH2AX foci are required for recruiting repair and checkpoint protein complexes to the replication break sites.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12660252     DOI: 10.1074/jbc.M300198200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  158 in total

1.  Phase I study of veliparib in combination with gemcitabine.

Authors:  Ronald Stoller; John C Schmitz; Fei Ding; Shannon Puhalla; Chandra P Belani; Leonard Appleman; Yan Lin; Yixing Jiang; Salah Almokadem; Daniel Petro; Julianne Holleran; Brian F Kiesel; R Ken Czambel; Benedito A Carneiro; Emmanuel Kontopodis; Pamela A Hershberger; Madani Rachid; Alice Chen; Edward Chu; Jan H Beumer
Journal:  Cancer Chemother Pharmacol       Date:  2017-08-02       Impact factor: 3.333

2.  Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression.

Authors:  Michael S Bobola; Douglas D Kolstoe; A Blank; John R Silber
Journal:  Mol Cancer Ther       Date:  2010-05       Impact factor: 6.261

3.  Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.

Authors:  Robert J Kinders; Melinda Hollingshead; Scott Lawrence; Jiuping Ji; Brian Tabb; William M Bonner; Yves Pommier; Larry Rubinstein; Yvonne A Evrard; Ralph E Parchment; Joseph Tomaszewski; James H Doroshow
Journal:  Clin Cancer Res       Date:  2010-10-05       Impact factor: 12.531

4.  Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.

Authors:  Dhriti Sooryakumar; Thomas S Dexheimer; Beverly A Teicher; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2011-06-02       Impact factor: 6.261

5.  Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base alkylation in vertebrate cells.

Authors:  Junko Murai; Shar-yin N Huang; Benu Brata Das; Thomas S Dexheimer; Shunichi Takeda; Yves Pommier
Journal:  J Biol Chem       Date:  2012-02-27       Impact factor: 5.157

6.  RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.

Authors:  S E Martin; Z-H Wu; K Gehlhaus; T L Jones; Y-W Zhang; R Guha; S Miyamoto; Y Pommier; N J Caplen
Journal:  Curr Cancer Drug Targets       Date:  2011-10       Impact factor: 3.428

7.  Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines.

Authors:  Keya Bandyopadhyay; Ruth A Gjerset
Journal:  Biochemistry       Date:  2011-01-12       Impact factor: 3.162

8.  DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.

Authors:  Stela S Palii; Beth O Van Emburgh; Umesh T Sankpal; Kevin D Brown; Keith D Robertson
Journal:  Mol Cell Biol       Date:  2007-11-08       Impact factor: 4.272

9.  Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation.

Authors:  Erik S Zimmerman; Junjie Chen; Joshua L Andersen; Orly Ardon; Jason L Dehart; Jana Blackett; Shailesh K Choudhary; David Camerini; Paul Nghiem; Vicente Planelles
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

10.  Death receptor-induced activation of the Chk2- and histone H2AX-associated DNA damage response pathways.

Authors:  Stéphanie Solier; Olivier Sordet; Kurt W Kohn; Yves Pommier
Journal:  Mol Cell Biol       Date:  2008-10-27       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.